Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading.

[1]  H. Deeg,et al.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  R. Hoffman,et al.  Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. , 2005, Blood.

[3]  J. Panse,et al.  Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis , 2005, British journal of haematology.

[4]  H. Deeg,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis. , 2003, Blood.

[5]  H. Deeg,et al.  Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. , 2003, Blood.

[6]  H. Deeg,et al.  Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  B. Clurman,et al.  Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation , 2002, Leukemia & lymphoma.

[8]  H. Deeg,et al.  Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. , 2001, Blood.

[9]  A. Tefferi.  Chronic myeloid disorders: Classification and treatment overview. , 2001, Seminars in hematology.

[10]  J. Raith,et al.  Acute myelofibrosis: multifocal bone marrow infiltration detected by scintigraphy and magnetic resonance imaging , 2000, Annals of Hematology.

[11]  H. Deeg,et al.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.

[12]  G. Gualdi,et al.  [The role of MRI in the valuation of disorders involving the bone marrow]. , 1997, La Clinica terapeutica.

[13]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[14]  R. Storb,et al.  Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. , 1995, Blood.

[15]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[16]  H. Kantarjian,et al.  The relevance of reticulin stain‐measured fibrosis at diagnosis in chronic myelogenous leukemia , 1987, Cancer.

[17]  H. Deeg,et al.  Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. , 1986, Blood.

[18]  R. Storb,et al.  Allogeneic bone marrow transplantation for chronic granulocytic leukemia. , 1981, Experimental hematology.

[19]  D. Bauermeister.  Quantitation of bone marrow reticulin--a normal range. , 1971, American journal of clinical pathology.

[20]  R. CorderoZuniga,et al.  [Agnogenic myeloid metaplasia]. , 1952, Revista medica de Costa Rica.